2026 Global: Biosimilar Contract Manufacturing Market-Competitive Review (2032) report
Description
The 2026 Global: Biosimilar Contract Manufacturing Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biosimilar contract manufacturing market by geography and historical trend. The scope of the report extends to sizing of the biosimilar contract manufacturing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The biosimilar contract manufacturing market features ten major companies dominating through advanced bioprocessing, strategic partnerships, and capacity expansions: Lonza, Samsung Biologics, WuXi Biologics, Catalent, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies (now Fujifilm Biotechnologies), Thermo Fisher Scientific, Pfizer, AGC Biologics, and Rentschler Biopharma. These leaders leverage cutting-edge technologies like single-use bioreactors, CHO cell lines, and continuous manufacturing to meet surging demand for cost-effective biosimilars in oncology, immunology, and inflammation. Lonza excels in comprehensive biologics services with global facilities, while Samsung Biologics reported KRW 1.29 trillion in Q2 2025 revenue, boosted by its Pfizer partnership for large-scale oncology biosimilar production. WuXi Biologics passed FDA inspections across five Chinese facilities in 2025, enhancing its drug substance and product capabilities, and Catalent supports GMP-compliant manufacturing with intensified fed-batch platforms.
Boehringer Ingelheim's BioXcellence division achieved €1.235 billion in 2025 revenue, driven by partnerships like its May 2024 deal with Quallent Pharmaceuticals, while FUJIFILM Diosynth opened a $3.2 billion Holly Springs site in September 2025, adding 8 x 20,000-L bioreactors for mammalian cell culture. Thermo Fisher Scientific strengthened its position via acquisitions like Solventum’s filtration business for $4.1 billion and Sanofi’s Ridgefield site, committing $2 billion to U.S. R&D and manufacturing. Pfizer collaborates extensively, including with Samsung for biosimilars and Biocon for insulin, capturing market share through oncology launches like ZIRABEV and RUXIENCE. AGC Biologics advances with a JPY 50 billion Yokohama facility set for 2027 GMP operations, supporting cell therapy and mRNA alongside its expanded Copenhagen site.
Rentschler Biopharma rounds out the top tier with robust process development and commercial-scale production, featured across market analyses for its reliability in biosimilar pipelines. These companies navigate regulatory hurdles via innovations like ProBioGen’s CHO.RiGHT technology—though not top ten, it exemplifies partnerships—and expansions such as UCB’s $5 billion U.S. biologics investment. Collectively, they hold 25-35% of global revenues, fostering affordability in emerging markets through Biocon-like cost efficiencies and Sandoz acquisitions, while addressing capacity gaps amid 37.7% regional growth projections. Their focus on quality control and sustainability shapes a market projected to reach USD 35.35 billion by 2032.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biosimilar contract manufacturing market by geography and historical trend. The scope of the report extends to sizing of the biosimilar contract manufacturing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The biosimilar contract manufacturing market features ten major companies dominating through advanced bioprocessing, strategic partnerships, and capacity expansions: Lonza, Samsung Biologics, WuXi Biologics, Catalent, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies (now Fujifilm Biotechnologies), Thermo Fisher Scientific, Pfizer, AGC Biologics, and Rentschler Biopharma. These leaders leverage cutting-edge technologies like single-use bioreactors, CHO cell lines, and continuous manufacturing to meet surging demand for cost-effective biosimilars in oncology, immunology, and inflammation. Lonza excels in comprehensive biologics services with global facilities, while Samsung Biologics reported KRW 1.29 trillion in Q2 2025 revenue, boosted by its Pfizer partnership for large-scale oncology biosimilar production. WuXi Biologics passed FDA inspections across five Chinese facilities in 2025, enhancing its drug substance and product capabilities, and Catalent supports GMP-compliant manufacturing with intensified fed-batch platforms.
Boehringer Ingelheim's BioXcellence division achieved €1.235 billion in 2025 revenue, driven by partnerships like its May 2024 deal with Quallent Pharmaceuticals, while FUJIFILM Diosynth opened a $3.2 billion Holly Springs site in September 2025, adding 8 x 20,000-L bioreactors for mammalian cell culture. Thermo Fisher Scientific strengthened its position via acquisitions like Solventum’s filtration business for $4.1 billion and Sanofi’s Ridgefield site, committing $2 billion to U.S. R&D and manufacturing. Pfizer collaborates extensively, including with Samsung for biosimilars and Biocon for insulin, capturing market share through oncology launches like ZIRABEV and RUXIENCE. AGC Biologics advances with a JPY 50 billion Yokohama facility set for 2027 GMP operations, supporting cell therapy and mRNA alongside its expanded Copenhagen site.
Rentschler Biopharma rounds out the top tier with robust process development and commercial-scale production, featured across market analyses for its reliability in biosimilar pipelines. These companies navigate regulatory hurdles via innovations like ProBioGen’s CHO.RiGHT technology—though not top ten, it exemplifies partnerships—and expansions such as UCB’s $5 billion U.S. biologics investment. Collectively, they hold 25-35% of global revenues, fostering affordability in emerging markets through Biocon-like cost efficiencies and Sandoz acquisitions, while addressing capacity gaps amid 37.7% regional growth projections. Their focus on quality control and sustainability shapes a market projected to reach USD 35.35 billion by 2032.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
